| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
| [0003]
|
| Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer
| [0003]
|
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
| [0003]
|
| Immunity
| [0085]
|
| Science
| [0085]
|
| Nat. Med.
| [0085]
|
| Microbiota: a key orchestrator of cancer therapy
| [0112]
|
| Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-Ll efficacy
| [0112]
|
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
| [0112]
|
| Gut Microbes May Up PD-1 Inhibitor Response
| [0112]
|
| Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn's disease
| [0112]
|
| Symbiotic gut microbes modulate human metabolic phenotypes
| [0112]
|
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
| [0112]
|